Login to Your Account



OSI Offering Garners $387M; Tarceva Waiting On Runway

By Randall Osborne


Friday, November 12, 2004
With 6 million shares offered at $64.50 each, OSI Pharmaceuticals Inc. is raising $387 million while waiting with partner Genentech Inc. for word from the FDA regarding Tarceva, their drug for non-small-cell lung cancer. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription